强化降脂对冠脉支架植入术后再狭窄的影响

Intensive lipid-lowering on restenosis after coronary stent implantation influence

目的：探讨阿托伐他汀强化降脂对DES再狭窄的影响。方法：选取本院2006~2011年收治的800例进行介入治疗的冠心病患者的临床资料,随机分为治疗组（420例）和对照组（380例）,治疗组用阿托伐他汀40mg,连用14d,后改为常规剂量20mg/d,对照组使用常规剂量10mg,连续应用15~20周,随访9个月,再次行冠状动脉造影检查,比较两组患者冠状动脉再狭窄的发生率及对血浆可溶性Fas的影响。结果：治疗组患者再狭窄率明显低于对照组,两组患者比较差异有统计学意义（P〈0.05）;治疗组患者血浆可溶性Fas与对照组患者比较有明显改善,两组患者比较差异有统计学意义（P〈0.05）。结论：阿托伐他汀能有效减少支架植入术后再狭窄,降低术后心血管事件的发生率,血浆可溶性Fas可成为预测再狭窄的有效指标。

Objective： To investigate the intensive lipid-lowering atorvastatin, the impact of DES restenosis. Methods： The hospital treated 2006 to 2011, 800 cases of patients were involved in the treatment of coronary heart disease in patients with clinical data, were randomly divided into treatment group （420 cases） and control group （380 cases）, The treatment group used atorvastatin 40 mg, repeat after 14 days, instead of regular doses of 20 mg/d, the control group used regular doses of 10 mg/d, continuous application of 15 to 20 weeks, follow-up of 9 months, coronary angiography again two groups were compared the incidence of coronary artery restenosis and the impact on plasma soluble Fas. Results： The patients with restenosis rate was significantly lower than the control group, the difference was statistically significant between two groups of patients （P〈0.05）; soluble Fas in patients treated with plasma compared with the control group patients improved significantly, the difference was statistically significant between two groups of patients （P〈0.05）. Conclusion： Atorvastatin can reduce restenosis after stent implantation, reducing the incidence of cardiovascular events after PCI, plasma soluble Fas may be an effective indicator of restenosis prediction.